Chemotherapy drug resistance mechanisms of hepatocellular carcinoma to arsenic trioxide

Abstract

Chen Yaoting, Hu Xiaojun, Li Dan, Shan Hong. Chemotherapy drug resistance mechanisms of hepatocellular carcinoma to arsenic trioxide[J]. Journal of International Oncology, 2016, 43(11): 861-864.

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262. ［2］ Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, doubleblind, placebocontrolled trial［J］. Lancet Oncol, 2015, 16(13): 1344-1354. DOI: 10.1016/S14702045(15) 001989. ［3］ de The H, Le Bras M, LallemandBreitenbach V. The cell biology of disease: acute promyelocytic leukemia, arsenic, and PML bodies［J］. J Cell Biol, 2012, 198(1): 11-21. DOI: 10.1083/jcb.201112044. ［4］ Emadi A, Gore SD. Arsenic trioxidean old drug rediscovered［J］. Blood Rev, 2010, 24(45): 191199. DOI: 10.1016/j.blre.2010.04.001. ［5］ Zhang X, Yang XR, Sun C, et al. Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma［J］. Cancer Lett, 2015, 366(1): 112122. DOI: 10.1016/j.canlet.2015.06.014. ［6］ Zheng T, Yin D, Lu Z, et al. Nutlin3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in hepatocellular carcinoma［J］. Mol Cancer, 2014, 13(5): 133-144. DOI: 10.1186/1476-4598-13-133. ［7］ Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo［J］. Adv Drug Deliv Rev, 2013, 65(1): 71-79. DOI: 10.1016/j.addr.2012.10.002. ［8］ Hua H, Qin S, Rui J, et al. Pharmacokinetics of arsenic trioxide (As(2)O(3)) in Chinese primary hepatocarcinoma patients［J］. Asian Pac J Cancer Prev, 2011, 12(1): 61-65. DOI:http://dx.doi.org/10.7314/APJCP.2011.12.1.61. ［9］ Ahn RW, Chen F, Chen H, et al. A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer［J］. Clin Cancer Res, 2010, 16(14): 3607-3617. DOI: 10.1158/1078-0432.CCR-10-0068. ［10］ Qian C, Wang Y, Chen Y, et al. Suppression of pancreatic tumor growth by targeted arsenic delivery with antiCD44v6 single chain antibody conjugated nanoparticles［J］. Biomaterials, 2013, 34(26): 6175-6184. DOI: 10.1016/j.biomaterials.2013.04.056. ［11］ Wilson GK, Tennant DA, McKeating JA. Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions［J］. J Hepatol, 2014, 61(6): 13971406. DOI: 10.1016/j.jhep.2014.08.025. ［12］ Warfel NA, ElDeiry WS. HIF1 signaling in drug resistance to chemotherapy［J］. Curr Med Chem, 2014, 21(26): 3021-3028. DOI: 10.2174/0929867321666140414101056. ［13］ Poller B, Wagenaar E, Tang SC, et al. Doubletransduced MDCKⅡ cells to study human Pglycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the bloodbrain barrier［J］. Mol Pharm, 2011, 8(2): 571-582. DOI: 10.1021/mp1003898. ［14］ Cao Y, Eble JM, Moon E, et al. Tumor cells upregulate normoxic HIF1alpha in response to doxorubicin［J］. Cancer Res, 2013, 73(20): 6230-6242. DOI: 10.1158/0008-5472.CAN-12-1345. ［15］ Liang Y, Zheng T, Song R, et al. Hypoxiamediated sorafenib resistance can be overcome by EF24 through Von HippelLindau tumor suppressordependent HIF1alpha inhibition in hepatocellular carcinoma［J］. Hepatology, 2013, 57(5): 1847-1857. DOI: 10.1002/hep.26224. ［16］ Liu Y, Zhang JB, Qin Y, et al. PROX1 promotes hepatocellular carcinoma metastasis by way of upregulating hypoxiainducible factor 1alpha expression and protein stability［J］. Hepatology, 2013, 58(2): 692705. DOI: 10.1002/hep.26398. ［17］ Li J, Xu Y, Long XD, et al. Cbx4 governs HIF1alpha to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity［J］. Cancer Cell, 2014, 25(1): 118-131. DOI: 10.1016/j.ccr.2013.12.008. ［18］ Khoo KH, Verma CS, Lane DP. Drugging the p53 pat hway: understanding the route to clinical efficacy［J］. Nat Rev Drug Discov, 2014, 13(3): 217-236. DOI: 10.1038/nrd4236. ［19］ He X, Liao J, Liu F, et al. Functional repair of p53 mutation in colorectal cancer cells using transsplicing［J］. Oncotarget, 2015, 6(4): 2034-2045. DOI: 10.18632/oncotarget.2988. ［20］ Gamell C, Jan Paul P, Haupt Y, et al. PML tumour suppression and beyond: therapeutic implications［J］. FEBS Lett, 2014, 588(16): 2653-2662. DOI: 10.1016/j.febslet.2014.02.007. ［21］ Liu ZM, Tseng JT, Hong DY, et al. Suppression of TGinteracting factor sensitizes arsenic trioxideinduced apoptosis in human hepatocellular carcinoma cells［J］. Biochem J, 2011, 438(2): 349-358. DOI: 10.1042/BJ20101653. ［22］ Guo XL, Li D, Sun K, et al. Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma［J］. J Mol Med (Berl), 2013, 91(4): 473483. DOI: 10.1007/s00109-012-0966-0. ［23］ Cojoc M, Mabert K, Muders MH, et al. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms［J］. Semin Cancer Biol, 2015, 31: 1627. DOI: 10.1016/j.semcancer.2014.06.004. ［24］ Rangwala F, Williams KP, Smith GR, et al. Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines［J］. BMC Cancer, 2012, 12(9): 402-412. DOI: 10.1186/1471-2407-12-402. ［25］ Hernanda PY, PedrozaGonzalez A, van der Laan LJ, et al. Tumor promotion through the mesenchymal stem cell compartment in human hepatocellular carcinoma［J］. Carcinogenesis, 2013, 34(10):2330-2340. DOI: 10.1093/carcin/bgt210. ［26］ He J, Wang M, Jiang Y, et al. Chronic arsenic exposure and angiogenesis in human bronchial epithelial cells via the ROS/miR-199a 5p/HIF-1alpha/COX-2 pathway［J］. Environ Health Perspect, 2014, 122(3): 255261. DOI: 10.1289/ehp.1307545. ［27］ Subbarayan PR, Ardalan B. In the war against solid tumors arsenic trioxide needs partners［J］. J Gastrointest Cancer, 2014, 45(3): 363-371. DOI: 10.1007/s12029-014-9617-8. ［28］ Liu B, Huang JW, Li Y, et al. Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a singleblind, randomized trial［J］. J Cancer Res Clin Oncol, 2015, 141(6): 1103-1108. DOI: 10.1007/s00432-014-1866-1.

[1]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[2]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[3]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311.
[4]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[5]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[6]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[7]	Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong.Effects of Anhydroicaritin on the proliferation， migration and apoptosis of hepatocellular carcinoma cells[J]. Journal of International Oncology, 2023, 50(9): 513-519.
[8]	Huang Hui, Ding Jianghua.Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma[J]. Journal of International Oncology, 2023, 50(9): 569-573.
[9]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[10]	Liu Li, Zhu Siqi, Sun Mengying, He Jingdong.Progress of PARP inhibitors in targeted therapy of small cell lung cancer[J]. Journal of International Oncology, 2023, 50(6): 368-372.
[11]	Liu Bohan, Huang Junxing.Research progress of solute carriers related genes in malignant tumors[J]. Journal of International Oncology, 2023, 50(5): 280-284.
[12]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240.
[13]	Li Jiaxuan, Feng Yinglu.Mechanism of action of glucocorticoid receptors in the growth of hepatoma cells[J]. Journal of International Oncology, 2023, 50(4): 241-243.
[14]	Deng Lili, Duan Xingyu, Li Baozhong.Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma[J]. Journal of International Oncology, 2023, 50(12): 751-757.
[15]	Liu Shaoping, Luo Hanchuan, Lin Shuhan, Luo Jiahui.Current status and research progress of interventional and systemic therapy for advanced hepatocellular carcinoma[J]. Journal of International Oncology, 2023, 50(12): 758-762.

Chemotherapy drug resistance mechanisms of hepatocellular carcinoma to arsenic trioxide

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments